|
?:abstract
|
-
PURPOSE to evaluate the blood level of anti-heart antibodies (AHA) and its correlation with clinical outcomes in patients with severe and moderate COVID-19. The study included 34 patients (23 males; mean age 60.2±16.6 years) with COVID-19 pneumonia. Besides standard medical examination the AHA blood levels were observed, including antinuclear antibodies (ANA), antiendothelial cell antibodies (AECA), anti-cardiomyocyte antibodies (AbC), anti-smooth muscle antibodies (ASMA) and cardiac conducting tissue antibodies (CCTA). Median hospital length of stay was 14 [13; 18] days. AHA levels were increased in 25 (73.5%) patients. Significant correlation (p<0.05) of AHA levels with cardiovascular manifestations (r = 0.459) was found. AbC levels correlated with pneumonia severity (r = 0.472), respiratory failure (r = 0.387), need for invasive ventilation (r = 0.469), chest pain (r = 0.374), low QRS voltage (r = 0.415) and levels of CRP (r = 0.360) and LDH (r = 0.360). ASMA levels were found to correlate with atrial fibrillation (r = 0.414, p<0.05). ANA and AbC levels correlated with pericardial effusion (r = 0.721 and r = 0.745 respectively, p<0.05). The lethality rate was 8.8%. AbC and ASMA levels correlated significantly with lethality (r = 0.363, and r = 0.426 respectively, p<0.05) and were prognostically important. AHA can be considered as part of the systemic immune and inflammatory response in COVID-19. Its possible role in the inflammatory heart disease requires further investigation. This article is protected by copyright. All rights reserved.
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}